Background: Kinase inhibitors targeting the BRAF V600 mutation have become standard in the treatment of metastatic melanoma. Albeit in wide clinical use, the patterns associated with therapy outcome are not fully elucidated. The present study was aimed to identify predictive factors of therapy response and survival under the BRAF inhibitor vemurafenib.
introduction
The systemic therapy of metastatic melanoma recently underwent considerable restructuring due to the introduction of two new groups of substances, blockers of molecules essential for the immune checkpoint such as CTLA-4 and PD-1/PD-L1, as well as inhibitors of molecules relevant for the mitogen-activated protein (MAP) kinase pathway such as BRAF and MEK. Agents from both substance groups were able to demonstrate a prolongation in overall survival (OS) in randomized phase-III trials [1] [2] [3] [4] , which has never been successfully shown before for any systemic therapy in metastatic melanoma. While for immune checkpoint blockers, specific immunologic conditions like expression of PD-L1 on tumor cells or presence of specific T-cell subsets in the circulation were identified as predictive markers of therapy response [5] , predictors of therapy outcome of MAP kinase pathway inhibitors have not yet been investigated in detail.
The present study was designed to identify clinical predictors of the therapy outcome in terms of response and survival under the BRAF inhibitor (BRAFi) vemurafenib. The candidate factors were chosen as to be available or measurable at therapy onset, so that they can be considered as decision factors when choosing a therapy modality for an individual patient. As candidate predictive factors to be investigated, we chose patient's age and gender, as well as tumor tissue's BRAF V600 mutation subtype. Also, established prognostic factors of stage IV melanoma were included, which were site of metastasis, patient's performance status, and serum lactate dehydrogenase (LDH). Since there is first evidence, that the presence and type of pretreatment might be of essential influence, we laid strong impact on the collection of data on all systemic therapies received by the studied patients before vemurafenib. All parameters were tested for their impact on patient survival by univariate and multivariate analysis, the latter to detect independent predictors of vemurafenib therapy outcome.
patients and methods study design
This multicenter retrospective study was initiated by the Dermatologic Cooperative Oncology Group (DeCOG), and undertaken with Ethics Committee approval (Ethics Committee, Medical School, Hannover, Germany; 1612-2012). Patients were accrued in the DeCOG study centers based on the following eligibility criteria: Histologically proven diagnosis of melanoma, unresectable metastatic disease in stage IV following the American Joint Committee on Cancer (AJCC) criteria [6] , detection of a BRAF V600 mutation in tumor tissue, and treatment with vemurafenib as a single agent either as per clinical trial or via prescription. Data were extracted from pre-existing patient files.
data collection
Patients were identified for study accrual via the electronic patient management systems of the respective clinical centers. Data were collected on standardized electronic record forms and merged in one central database before analysis. Data comprised patient demographics, BRAF V600 mutation subtype, site of metastasis, overall performance status (OPS) graded by Eastern Cooperative Oncology Group (ECOG) criteria, and serum LDH concentration, all at onset of vemurafenib treatment. For categorization of metastatic sites, we modified the AJCC M category [6] by grouping by localization of metastasis only regardless of serum LDH. The groups were (i) metastases to skin and/or lymph nodes (skin/LN); (ii) metastases to the lung (lung); (iii) metastases to other organs (other organs); and (iv) metastases to the brain or central nervous system (brain/CNS). Data on systemic therapies received by the patients while in stage IV but before onset of vemurafenib were recorded as pretreatment. Pretreatment was categorized into (i) regimens containing chemotherapeutic agents (chemotherapy); (ii) regimens containing immunotherapeutic agents (immunotherapy); and (iii) regimens containing kinase inhibitors (kinase inhibitors). Thus, patients pre-treated with combination therapies (e.g. biochemotherapy) or with multiple regimens were assigned to more than one therapy category. Collected data on the course and outcome of vemurafenib treatment included therapy duration, best response following RECIST criteria [7] or comparable classification systems categorizing into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), as well as progression-free (PFS) and overall survival (OS). Therapeutic procedures taking part after vemurafenib treatment were not recorded.
statistical analysis
OS and PFS were calculated from onset of vemurafenib until death or disease progression, respectively. If no such event occurred, the date of last patient contact was used as survival end point (censored observation). Survival curves, hazard ratios, and median survival times were calculated using the Kaplan-Meier method for censored failure time data. Ninety-five percent confidence intervals (CIs) for survival times were calculated using the method of Brookmeyer [8] . The log-rank test was used for univariate comparison of survival probabilities. The proportional hazards model of Cox was applied to test for multivariate independent predictors of survival in adjustment with appropriate clinical covariates. Differences in response were calculated using Fisher's exact test. All presented P values are two-tailed and unadjusted for potential multiple comparisons to allow a hypothesisgenerating exploratory data analysis; P <0.05 was considered statistically significant.
results patient characteristics
Data were collected of 300 patients from 14 clinical centers in Germany and Austria. A total of 170 patients (56.7%) received vemurafenib within the safety trial (NCT01307397; [9] ), 28 (9.3%) within the BRIM-3 trial (NCT01006980; [2] ), and 102 (34.0%) by prescription. Detailed patient characteristics are presented in Table 1 . The BRAF V600 mutation status was specified by gene sequencing in 65% of patients; for the remaining patients, only the positive result of a commercial test (cobas BRAF V600 mutation test; Roche Diagnostics, Rotkreuz, Switzerland) was available.
vemurafenib therapy and outcome
The study database was closed in December 2013; median follow-up time was 13.0 months. Therapy characteristics are presented in supplementary Table S1, available at Annals of Oncology online. Median therapy duration was 5.3 months. All patients started with 960 mg vemurafenib b.i.d.; 12.7% needed a dose reduction due to side-effects. At database closure, 48.0% of the patients had died. Of the patients alive, 52.6% were still on vemurafenib treatment. Disease progression or relapse was observed in 69.0% of patients, of whom 43.5% received vemurafenib beyond progression. As best response, 57.7% of patients achieved CR or PR, 22.3% showed SD, and 15.7% revealed disease progression. The median progression-free survival (PFS) was 5.1 months (95% CI 0.9-21.6 months]; the median OS was 7.6 months (95% CI 1.0-22.9 months). univariate analysis of gender, age, and BRAF v600 mutation subtype
We found a trend toward favorable survival in males compared with females ( Figures 1A and 2 ), not reaching statistical significance. Older patients revealed a significantly better survival outcome than younger patients, with a cutoff at 55 years calculated as the optimal threshold ( Figures 1B and 2) . Patients harboring the V600E mutation showed a significantly better clinical response than patients carrying the V600K mutation (P = 0.016; Table 2 ). However, the mutation subtype did not show a significant influence on survival in univariate analysis (Figure 2A and B) . Notably, patients harboring the V600E mutation showed a median PFS of 6.7 months compared with 4.9 months only observed in patients with the V600K mutation (P = 0.33); similarly, the OS of patients with the V600E mutation was 12.4 versus 10.7 months in patients carrying V600K (P = 0.51). univariate analysis of serum LDH, performance status, and site of metastasis Serum LDH was determined in 96.3% of the studied patients. Patients with an LDH level above the upper normal limit (UNL) had a significantly impaired survival ( Figures 1C and 2 ). This survival disadvantage was highly significant for PFS [hazard ratio (HR) = 1.70; 95% CI 1.28-2.24; P = 0.00023] as well as OS (HR = 2.11; 95% CI 1.50-2.97; P = 0.00002), and became even more obvious when patients with LDH serum levels above twice the UNL were analyzed (supplementary Figure S1 , available at Annals of Oncology online). Moreover, patients presenting elevated serum LDH revealed a significantly impaired response to vemurafenib (P = 0.0000001; Table 2 ). OPS was available in 96.0% of the studied patients. Patients presenting a normal OPS [Eastern Cooperative Oncology Group (ECOG = 0)] at therapy onset revealed a definitely better survival than patients with an impaired OPS (ECOG ≥1), Figures 1D and 2. This survival difference was very high for PFS (HR = 0.50; 95% CI 0.38-0.67; P < 0.00001) and OS (HR = 0.50; 95% CI 0.38-0.67; P = 0.00005). Moreover, patients with normal OPS revealed a significantly better clinical response to vemurafenib (P = 0.00089; Table 2 ). The metastatic sites at vemurafenib onset were available in 95.3% of patients. They had no significant impact on PFS (Figures 1E and 2); however, there were considerable trends between the four groups. Regarding OS, patients presenting skin/lymph node (LN) metastases revealed the best OS (HR = 0.62; 95% CI 0.36-1.06; P = 0.08) and patients with brain/central nervous system (CNS) metastases showed the worst survival (HR = 1.64; 95% CI 1.14-2.36; P = 0.0075). Of 66 patients with brain/CNS metastases, 42 (63.6%) had a radiation therapy of brain lesions before vemurafenib treatment. Best response in patients with brain/CNS metastases was 0 CR (0%), 38 PR (57.6%), 14 SD (21.2%), and 10 PD (15.2%); in four patients, best response was not evaluable.
univariate analysis of pretreatment
Data on systemic pretreatments were available for all studied patients ( Table 1 ). In total, 43.3% of patients were pretreated, resulting in a significantly impaired PFS (HR = 1.41; 95% CI 1.07-1.86; P = 0.015), and translating into a trend toward an unfavorable OS (HR = 1.27; 95% CI 0.91-1.77; P = 0.16); Figures 2 and 3A. Of pretreated patients, 90.0% received chemotherapy, 30.8% received immunotherapy, and 15.4% received kinase inhibitors (supplementary Table S2 , available at Annals of Oncology online). With regard to these three pretreatment subtypes, chemotherapy (HR = 1.43; 95% CI 1.09-1.88; P = 0.011) and kinase inhibitors (HR = 1.37; 95% CI 0.79-2.36; P = 0.26) led to a similarly reduced PFS, while immunotherapy resulted in a favorable PFS (HR = 0.65; 95% CI 0.43-0.98; P = 0.045); Figures 2 and 3B. For OS, kinase inhibitor pretreatment resulted in a significant impairment (HR = 1.78; 95% CI 1.09-2.92; P = 0.021), chemotherapy led to a slight impairment (HR = 1.20; 95% CI 0.86-1.68; P = 0.28), and immunotherapy turned out as favorable (HR = 0.63; 95% CI 0.37-1.09; P = 0.097); Figures 2 and 3B. Analyzing the subtypes of chemotherapy, no significant survival differences could be observed between monochemotherapy and polychemotherapy (Figure 2A and B) . For immunotherapy, all three therapy subtypes (vaccination, checkpoint blockers, and other immunotherapies) were associated with a similarly (Figure 2A and B) . Concerning kinase inhibitor therapy, MEK inhibitor (MEKi) pretreatment resulted in a highly impaired survival, which in univariate analysis reached significance for OS but not for PFS (Figure 2A and B 
discussion
Vemurafenib is a selective inhibitor of V600-mutated BRAF, and was the first-in-class MAP kinase pathway inhibitor to gain approval for the treatment of melanoma after it showed a significant survival benefit when compared with the standard chemotherapy dacarbazine [2] . Currently, vemurafenib is widely used in BRAF V600-mutated melanoma, with no validated tools available to predict therapy outcome. The most important finding of our present study is the strong influence of pretreatment on the outcome of vemurafenib therapy. First, our data indicate that patients with no pretreatment have a better survival outcome than patients who received any kind of previous therapy. Considering the type of pretreatment, stepwise regression multivariate analysis revealed immunotherapy pretreatment as the second strongest independent predictor of PFS. Likewise, immunotherapy pretreatment was an independent predictor for OS. In contrast, chemotherapy and kinase inhibitor pretreatment both revealed a negative impact on survival. Thus, according to our results, a previous immunotherapy does not impair survival under subsequent vemurafenib as seen with chemotherapy or kinase inhibitor pretreatment. Strikingly, this effect remains valid whether a patient received immunotherapeutics only or also other types of therapies like chemotherapy or kinase inhibitors ahead of vemurafenib. It should be noted that the effect of pretreatment on OS might additionally be affected by any type of treatment received by the studied patients after vemurafenib therapy; however, since these effects are in line with those seen in PFS, an additional effect of subsequent therapy lines seems unlikely. This question remains open, since data of subsequent therapies as per definition are not part of this study.
Pretreatment as a candidate predictive factor of vemurafenib therapy outcome is of special importance, since in daily clinical practice the open question on the optimal strategy of therapy sequencing is an urgent issue. Our data indicate that the application of chemotherapy or kinase inhibitor therapy, at least with MEKis, impairs a patient's survival under subsequently given vemurafenib, when compared with a prior immunotherapy or to no pretreatment. In 2013, we reported a retrospective study on therapy sequencing showing that treatment with MEKi before BRAFi results in a better outcome than BRAFi first and MEKi thereafter [10] . Our present data show that the sequencing of MEKi before vemurafenib results in an impaired survival, and this even in multivariate testing. Thus, it can be concluded that MEKi before BRAFi might be better than vice versa, but is inferior to prior immunotherapy or no therapy and, therefore, is no recommendable therapy sequence in BRAF V600-mutated melanoma.
The interpretation of our results with regard to immunotherapy pretreatment is more difficult. The survival curves of patients who received immunotherapy before vemurafenib lie above the survival curves of patients without any pretreatment; however, these differences do not reach statistical significance ( Figure 3B ). Thus, it can be concluded that the application of immunotherapeutics before giving vemurafenib does not impair a patient's survival compared with giving vemurafenib as firstline therapy. This finding, if further validated and prospectively confirmed in larger patient numbers, would be of particular interest for the current debate on the clinical choice: immunotherapy first or BRAFi first? A recent retrospective study showed, that an immunotherapy pretreatment did not impair response and survival of a subsequent MAPKi therapy [11] .
That study report also presented Kaplan-Meier survival curves of patients pretreated with immunotherapy as superior to those of patients with no pretreatment, although not reaching statistical significance. Another retrospective study analyzing patient outcome after different sequential therapy schedules [12] found a significantly better OS in patients treated with ipilimumab first when compared with patients who received BRAFi first. Moreover, our results from multivariate analysis reveal that two of the established prognostic factors of stage IV melanoma, serum LDH and OPS, were among the strongest predictors of vemurafenib therapy outcome. Serum LDH elevation and reduced OPS have been identified already to be associated with an impaired outcome of vemurafenib [9, 13] . However, our findings indicate that the OPS should gain more emphasis in the clinical setting, since it was by far the strongest predictor for PFS. The site of metastasis was expected to be an independent predictor of survival, since patients with AJCC M1c disease were reported to have a significantly worse survival under vemurafenib than patients in M1a/b [2, 13, 14] . Surprisingly, our multivariate data analysis revealed no independent impact of the metastatic site on PFS or OS. However, it should be noted that we analyzed serum LDH and site of metastasis separately as distinct candidate predictive factors while, in the AJCC classification, both parameters are combined. Thus, our findings indicate that the negative therapy outcome of vemurafenib yet described in M1c patients might be mainly due to elevated serum LDH and not predominantly to specific sites of metastasis. In particular, it should be noted that, in our study population, patients with brain/CNS metastases revealed a response profile similar to that of the overall patient population so that brain metastases seem to be no obstacle for an objective response to vemurafenib. However, it should be noted that previous results in a larger patient population showed brain metastasis to be associated with a significantly worse outcome of vemurafenib therapy [9] .
Interestingly, our analyses demonstrated patient age and gender as independent predictors of survival under vemurafenib. Higher age at therapy onset was strongly associated with better PFS and OS. This finding is unexpected, with up to now, higher patient age has only been reported to be associated with higher incidences and increased grades of adverse events [9] . With regard to gender, we found male patients to be superior to female patients in terms of survival under vemurafenib. This is interesting, since in stage IV melanoma, usually immunotherapy strategies tend to show stronger benefits in female patients [15] , while chemotherapy approaches show better survival in males [16] . Thus, concerning vemurafenib, gender shows a pattern of impact similar to that found in chemotherapy. The BRAF V600 mutation subtype revealed no significant impact on survival in our patient population, whereas response to vemurafenib was significantly worse in V600K-compared with V600E-mutated BRAF. The impact of BRAF V600 mutation subtypes on vemurafenib therapy outcome has not been studied before in detail. Menzies et al. described a shorter time to distant metastasis in patients with primary melanomas carrying the V600K mutation compared with those with V600E [17] . Nevertheless, the survival times of both patient groups after diagnosis of distant metastasis showed no significant difference. Previous data revealed that patients carrying a V600K mutation presented a comparable survival under vemurafenib as patients carrying the common mutation V600E [14] . Interestingly, the observed objective response rate was higher in BRAF V600E than in BRAF V600K patients (59% versus 45%), which is in line with the results of our study.
Regarding our study in comparison with the published data from the large international safety trial of vemurafenib in metastatic melanoma [9] , it becomes obvious that the characteristics of the two study populations are highly similar, particularly concerning median patient age and the distribution patterns of gender, serum LDH, and brain metastasis. However, the ECOG OPS was categorized differently in both studies (0 versus ≥1; and 0-1 versus ≥2) and, in our study, the sites of metastasis were analyzed separately from serum LDH. Most importantly, the study by Larkin et al. did not analyze the impact of subtypes of systemic pretreatment on the outcome of vemurafenib therapy.
Finally, it should be mentioned that monotherapy with a BRAFi-like vemurafenib will no longer be standard of care in the following years. Following the results of a number of recent clinical trials [18] [19] [20] , a combination therapy with BRAFi and MEKi will replace a monotherapy with any of both inhibitors as standard treatment of BRAF-mutated melanoma. Thus, the results obtained in our present study should also be analyzed in combinatory treatment settings including BRAFi.
Taken together, it can be concluded from our study results that melanoma patients carrying the BRAF V600 mutation can be offered a first-line immunotherapy without impairing the outcome of a subsequent treatment with vemurafenib. In contrast, the sequencing of chemotherapy or MEKis as first-line therapy worsen a second-line vemurafenib therapy outcome and therefore cannot be recommended for this patient group. The conclusions drawn from the results of our study are limited because it is of retrospective nature and thus susceptible to selection bias. However, its multicenter design attenuates this potential selection bias, rendering the study results superior to those emerging from oligocenter or monocenter retrospective studies. The conclusions drawn need validation in prospective studies; this is particularly true for the validation of the pretreatment type as an independent predictor of vemurafenib therapy outcome.
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